Clinical Trial Update: Pharmacodynamic Effects of Sacubitril/Valsartan on Natriuretic Peptides, Angiotensin and Neprilysin [Phase 4]

View source ↗

Summary

Phase 4 trial update evaluating pharmacodynamic effects of sacubitril/valsartan on natriuretic peptides, angiotensin, and neprilysin in heart failure with reduc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Reduced Ejection Fraction

Drugs mentioned

• Sacubitril/Valsartan (sacubitril/valsartan)

Snippet

Sponsor: Oslo University Hospital | Conditions: Heart Failure, Systolic | Phase 4 | Status: UNKNOWN